Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®

First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research FacilityMHRA approves continuation of Invizius's first-in-human clinical study following a prearranged two-patient safety and performance reviewStudy is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysisView original content:https://www.prnewswire.co.uk/news-releases/invizius-treats-first-patients-in-first-in-human-phase-1-clinical-study-of-lead-dialysis-product-h-guard-302055006.html

en | boerse | 67988334 |